Special Issue "Epstein–Barr Virus Associated Cancers"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2018)
The Epstein-Barr virus (EBV) is a double-stranded DNA gamma-1 herpesvirus. Over 90% of adults worldwide are infected and most have a lifelong asymptomatic infection. Infected cells, primarily resting memory B cells in peripheral blood, provide a permanent reservoir for the virus. EBV-associated cancer is an occasional outcome of the processes supporting infection persistence, but does not contribute substantially to continuation of infection in the individual host nor in the host population.
Globally, EBV is associated with an estimated 200,000 new cases each year of a diverse group of malignancies, including lymphoid cancers (endemic Burkitt, Hodgkin, and NK/T-cell and immunosuppression-related non-Hodgkin lymphomas), epithelial cancers (nasopharyngeal and some forms of gastric cancers), and pediatric leiomyosarcoma. For several of these cancer types, both EBV-positive and -negative tumors may occur that are clinically indistinguishable, which complicates evaluation of the contribution of virus infection to the development of these malignancies. In addition to epidemiologic evidence, mechanistic considerations include the proportion of virus-positive cases in a given tumor type, the proportion of tumor cells that carry the virus, the clonality of the viral genome, the pattern of EBV gene expression in tumor cells and their precursors, and the role of EBV strain variation in oncogenesis. EBV-specific immune responses are important in controlling tumor outgrowth but complex interactions in the local tumor microenvironment can result in immune evasion.
EBV was the first human cancer virus discovered when it was found to be associated with Burkitt lymphoma over fifty years ago and, in 1984, EBV was the first human virus sequenced. Studies of EBV-associated cancers have advanced scientific understanding of both viral biology and underlying pathways of carcinogenesis. The virus also represents a potential target for novel cancer diagnostic and therapeutic approaches, including the possibility of prevention by vaccination. This Special Issue will highlight current knowledge of EBV-associated cancers, spanning basic biology, human epidemiology and potential clinical implications.Dr. Charles Rabkin
Prof. Lawrence S. Young
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.